David Ferguson - Joint Stock Head Relations
| KSPI Stock | 96.94 2.65 2.66% |
Executive
David Ferguson is Head Relations of Joint Stock
| Age | 47 |
| Address | 154A, Nauryzbai Batyr Street, Almaty, Kazakhstan, 050013 |
| Phone | 7 727 330 6710 |
| Web | https://ir.kaspi.kz |
Joint Stock Management Efficiency
The company has return on total asset (ROA) of 0.1571 % which means that it generated a profit of $0.1571 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.7898 %, meaning that it created $0.7898 on every $100 dollars invested by stockholders. Joint Stock's management efficiency ratios could be used to measure how well Joint Stock manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Joint Stock's Return On Tangible Assets are increasing as compared to previous years. The Joint Stock's current Return On Equity is estimated to increase to 0.81, while Return On Capital Employed is projected to decrease to 0.54. As of now, Joint Stock's Return On Tangible Assets are increasing as compared to previous years. The Joint Stock's current Intangibles To Total Assets is estimated to increase to 0.01, while Total Assets are projected to decrease to under 5.9 T.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cara Miller | Tarsus Pharmaceuticals | N/A | |
| Meriam Kabbaj | Genfit | 51 | |
| MD MBE | Spyre Therapeutics | 66 | |
| Joshua MD | Spyre Therapeutics | N/A | |
| Neera Clase | Tarsus Pharmaceuticals | N/A | |
| Eric McIntyre | Spyre Therapeutics | N/A | |
| James Myers | Spyre Therapeutics | N/A | |
| Aziz MBA | Tarsus Pharmaceuticals | 47 | |
| Emilie Desodt | Genfit | 41 | |
| Justin LaFountaine | Spyre Therapeutics | N/A | |
| MD JD | Tarsus Pharmaceuticals | 46 | |
| Kelly Boothe | Spyre Therapeutics | N/A | |
| Scott Burrows | Spyre Therapeutics | 47 | |
| John Brozek | Genfit | 47 | |
| CFE CPA | Spyre Therapeutics | N/A | |
| Andrew Spencer | Spyre Therapeutics | N/A | |
| Laurent Lannoo | Genfit | 54 | |
| Sakina SayahJeanne | Genfit | 52 | |
| Matthew MBA | Tarsus Pharmaceuticals | 47 | |
| James JD | Spyre Therapeutics | 52 | |
| Paul JD | Spyre Therapeutics | 59 | |
Management Performance
| Return On Equity | 0.79 | ||||
| Return On Asset | 0.16 |
Joint Stock Leadership Team
Elected by the shareholders, the Joint Stock's board of directors comprises two types of representatives: Joint Stock inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Joint. The board's role is to monitor Joint Stock's management team and ensure that shareholders' interests are well served. Joint Stock's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Joint Stock's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tengiz Mosidze, Deputy CFO | ||
| Kanat Aitenov, Head Network | ||
| David Ferguson, Head Relations | ||
| Mamuka Kirvalidze, Head Business | ||
| Yuri Didenko, Deputy Board | ||
| Oleg Bakhmutov, Head People | ||
| Arseniy Kochetkov, Head Services | ||
| Pavel Mironov, COO Board | ||
| Nailya Ualibekova, Chief Accountant | ||
| Sabyrzhan Berkinbaev, Head Legal | ||
| Mikheil Lomtadze, Executive CoFounder | ||
| Saltanat Zhumabay, Head Products |
Joint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Joint Stock a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.79 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.76 % | ||||
| Current Valuation | 15.21 B | ||||
| Shares Outstanding | 190.02 M | ||||
| Shares Owned By Insiders | 37.92 % | ||||
| Shares Owned By Institutions | 49.66 % | ||||
| Number Of Shares Shorted | 904.04 K | ||||
| Price To Book | 5.92 X |
Currently Active Assets on Macroaxis
When determining whether Joint Stock offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Joint Stock's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Joint Stock Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Joint Stock Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Joint Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Joint Stock please use our How to Invest in Joint Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Consumer Finance space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Joint Stock. If investors know Joint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Joint Stock listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Dividend Share 2.5 K | Earnings Share 10.98 | Revenue Per Share | Quarterly Revenue Growth 0.304 |
The market value of Joint Stock is measured differently than its book value, which is the value of Joint that is recorded on the company's balance sheet. Investors also form their own opinion of Joint Stock's value that differs from its market value or its book value, called intrinsic value, which is Joint Stock's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Joint Stock's market value can be influenced by many factors that don't directly affect Joint Stock's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Joint Stock's value and its price as these two are different measures arrived at by different means. Investors typically determine if Joint Stock is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Joint Stock's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.